RIL
DSGN icon

Rothschild Investment LLC’s Design Therapeutics DSGN Stock Holding History

Rothschild Investment LLC’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$245 Buy
+23
New +$233 ﹤0.01% 3271

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Rothschild Investment LLC's DSGN Position: Q1 2026 in Review

Rothschild Investment LLC opened a new position in Design Therapeutics (DSGN) in Q1 2026: 23 shares worth $245. The stake represents ﹤0.01% of the portfolio and ranks #3271 among its holdings.

125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Rothschild Investment LLC held 23 shares of Design Therapeutics worth $245 as of Q1 2026.
  • Design Therapeutics was a new Rothschild Investment LLC position in Q1 2026.
  • Design Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q1 2026, its #3271 holding.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Rothschild Investment LLC's 13F filing for Q1 2026, filed 7 May 2026.